Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

ClinicalTrials.gov ID: NCT07177339

Public ClinicalTrials.gov record NCT07177339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 28, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as add-on Treatment in COPD Patients With Type 2 Inflammation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

Study identification

NCT ID
NCT07177339
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,196 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 19, 2025
Primary completion
Apr 29, 2029
Completion
Jun 7, 2029
Last update posted
Jul 27, 2026

2025 – 2029

United States locations

U.S. sites
42
U.S. states
16
U.S. cities
38
Facility City State ZIP Site status
GSK Investigational Site Newport Beach California 92663 Recruiting
GSK Investigational Site Lakewood Colorado 80228-1813 Recruiting
GSK Investigational Site Brandon Florida 33511 Recruiting
GSK Investigational Site Crystal River Florida 34429 Recruiting
GSK Investigational Site Doral Florida 33172 Recruiting
GSK Investigational Site Greenacres City Florida 33467 Recruiting
GSK Investigational Site Hialeah Florida 33012 Recruiting
GSK Investigational Site Hollywood Florida 33024 Recruiting
GSK Investigational Site Miami Florida 33125 Recruiting
GSK Investigational Site Miami Florida 33126 Recruiting
GSK Investigational Site Miami Florida 33176 Recruiting
GSK Investigational Site Miami Lakes Florida 33016 Recruiting
GSK Investigational Site Orlando Florida 32825 Recruiting
GSK Investigational Site Cordele Georgia 31015 Recruiting
GSK Investigational Site Dunwoody Georgia 30350 Recruiting
GSK Investigational Site Boise Idaho 83702 Recruiting
GSK Investigational Site Bowling Green Kentucky 42101 Recruiting
GSK Investigational Site Lake Charles Louisiana 70605 Recruiting
GSK Investigational Site Shreveport Louisiana 71105 Recruiting
GSK Investigational Site Bangor Maine 04401 Recruiting
GSK Investigational Site Allen Park Michigan 48101 Recruiting
GSK Investigational Site Clarkston Michigan 48346 Recruiting
GSK Investigational Site Dearborn Michigan 48126 Recruiting
GSK Investigational Site Henderson Nevada 89052 Recruiting
GSK Investigational Site Las Vegas Nevada 89123 Recruiting
GSK Investigational Site Reno Nevada 89502 Recruiting
GSK Investigational Site Winston-Salem North Carolina 27103 Recruiting
GSK Investigational Site Edmond Oklahoma 73013 Recruiting
GSK Investigational Site DuBois Pennsylvania 15801 Recruiting
GSK Investigational Site West Chester Pennsylvania 19380 Recruiting
GSK Investigational Site Greenville South Carolina 29607 Recruiting
GSK Investigational Site Rock Hill South Carolina 29732 Recruiting
GSK Investigational Site Knoxville Tennessee 37919 Recruiting
GSK Investigational Site Dallas Texas 75254 Recruiting
GSK Investigational Site DeSoto Texas 75115 Recruiting
GSK Investigational Site Greenville Texas 75401 Recruiting
GSK Investigational Site Houston Texas 77058 Recruiting
GSK Investigational Site Houston Texas 77089 Recruiting
GSK Investigational Site Houston Texas 77090 Recruiting
GSK Investigational Site Katy Texas 77494 Recruiting
GSK Investigational Site Mesquite Texas 75149 Recruiting
GSK Investigational Site Stafford Texas 77477 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.

Recently updated Pulmonary Disease, Chronic Obstructive trials

Other public records listing Pulmonary Disease, Chronic Obstructive. Sorted by last update posted; newest first. Not a recommendation.

All Pulmonary Disease, Chronic Obstructive trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07177339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 27, 2026 · Synced Jul 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07177339 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →